Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 3/20 | 0.31 |
| ▸ | KCNQ1 | P51787 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313709 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4AHRMEN1KMT2A | |
| SCHEMBL31539835 | 0.82 | MEN1 (0.33) | MEN1KMT2AMAPT | |
| SCHEMBL14868720 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNA4AHRMEN1KMT2A | |
| SCHEMBL11293610 | 0.73 | MAPT (0.33) | MEN1KMT2AMAPT | |
| SCHEMBL21684665 | 0.73 | ALDH1A1 (0.44) | AHRMEN1KMT2AMAPT | |
| SCHEMBL31523267 | 0.72 | MAPK1 (0.41) | MEN1KMT2AMAPT | |
| SCHEMBL19462480 | 0.72 | TGFBR1 (0.38) | TGFBR1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL656880 | 0.71 | CDK2 (0.48) | MEN1KMT2AMAPT | |
| SCHEMBL16165291 | 0.70 | KCNQ3 (0.40) | TGFBR1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL17512681 | 0.69 | TDP1 (0.46) | AHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | CHRNB2 4848/4885CHRNA4 4376/4885TGFBR1 4649/4885 |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | CHRNB2 1431/4885CHRNA4 1139/4885TGFBR1 295/4885 |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNA4 4570/4885TGFBR1 2789/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNA4 4570/4885TGFBR1 2789/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNA4 4570/4885TGFBR1 2789/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CHRNB2 3519/4885CHRNA4 4570/4885TGFBR1 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.